Bruker Corporation
Health Care · Life Sciences Tools & Services
4B revenue split across BSI Life Science (mass spec + NMR + spatial biology), BSI NANO (microscopy + semi metrology + X-ray), and BSI CALID, plus a small BEST superconductor segment. Spatial biology rollup (NanoString CosMx, Canopy, PhenoImager) repositions BRKR from instruments-only to instruments + consumables in the fastest-growing slice of biopharma R&D.
- timsTOF mass spec franchise compounding double-digits; differentiated 4D proteomics vs $TMO Orbitrap
- Spatial biology TAM ($3-5B by 2030) with installed-base + consumable pull-through after NanoString deal
- Semi/applied exposure via Nano segment levers $ASML/$AMAT capex cycle without pure-cyclical beta
- Owner-operator culture (Laukien family ~25%) - long capital-allocation horizon vs peers
- Pharma R&D budget freeze + China academic funding cuts pressure 2025-2026 instruments orders
- Spatial biology M&A stack lifted leverage (~2.5x net debt/EBITDA) ahead of integration risk
- Gross margins (~50%) structurally below $TMO/$DHR (~55-60%) - consumables mix shift slow
- NIH/academic exposure (~30% of life-sci revenue) is policy-sensitive into US budget cycle
No major news in the last 7 days for BRKR - only listicles and opinion pieces, which we filter out by default. See everything anyway.